AUSTRALIAN Pharmaceutical Industries (API) has highlighted its FY18 ongoing upward trend of compound annual growth rate (CAGR) and return on equity (ROE) in its CEO Connect report.
The ASX announcement via powerpoint showed revenue of $4.0 billion, underlying EBITDA of $119 million, yielding 11.1c earnings per share and total dividends of 7.5c/share.
The future strength and stability was focused on evolving Priceline Pharmacy, expanding Clearskincare, building consumer brands and growing via the possible merger with Sigma.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Feb 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Feb 19
